Cargando…
COVID-19 is not associated with worse long-term inflammatory bowel disease outcomes: a multicenter case–control study
BACKGROUND: Inflammatory bowel disease (IBD) is not associated with worse coronavirus disease 2019 (COVID-19) outcomes. However, data are lacking regarding the long-term impact of severe acute respiratory syndrome coronavirus 2 infection on the disease course of IBD. OBJECTIVES: We aimed to investig...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9637830/ https://www.ncbi.nlm.nih.gov/pubmed/36348637 http://dx.doi.org/10.1177/17562848221132363 |
_version_ | 1784825268275249152 |
---|---|
author | Hong, Simon J. Bhattacharya, Sumona Aboubakr, Aiya Nadkarni, Devika Lech, Diana Ungaro, Ryan C. Agrawal, Manasi Hirten, Robert P. Greywoode, Ruby Mone, Anjali Chang, Shannon Hudesman, David P. Ullman, Thomas Sultan, Keith Lukin, Dana J. Colombel, Jean-Frederic Axelrad, Jordan E. |
author_facet | Hong, Simon J. Bhattacharya, Sumona Aboubakr, Aiya Nadkarni, Devika Lech, Diana Ungaro, Ryan C. Agrawal, Manasi Hirten, Robert P. Greywoode, Ruby Mone, Anjali Chang, Shannon Hudesman, David P. Ullman, Thomas Sultan, Keith Lukin, Dana J. Colombel, Jean-Frederic Axelrad, Jordan E. |
author_sort | Hong, Simon J. |
collection | PubMed |
description | BACKGROUND: Inflammatory bowel disease (IBD) is not associated with worse coronavirus disease 2019 (COVID-19) outcomes. However, data are lacking regarding the long-term impact of severe acute respiratory syndrome coronavirus 2 infection on the disease course of IBD. OBJECTIVES: We aimed to investigate the effect of COVID-19 on long-term outcomes of IBD. DESIGN: We performed a multicenter case–control study of patients with IBD and COVID-19 between February 2020 and December 2020. METHODS: Cases and controls were individuals with IBD with presence or absence, respectively, of COVID-19-related symptoms and confirmatory testing. The primary composite outcome was IBD-related hospitalization or surgery. RESULTS: We identified 251 cases [ulcerative colitis (n = 111, 45%), Crohn’s disease (n = 139, 55%)] and 251 controls, with a median follow-up of 394 days. The primary composite outcome of IBD-related hospitalization or surgery occurred in 29 (12%) cases versus 38 (15%) controls (p = 0.24) and on multivariate Cox regression, COVID-19 was not associated with increased risk of adverse IBD outcomes [adjusted hazard ratio (aHR): 0.84, 95% confidence interval [CI]: 0.44–1.42]. When stratified by infection severity, severe COVID-19 was associated with a numerically increased risk of adverse IBD outcomes (aHR: 2.43, 95% CI: 1.00–5.86), whereas mild-to-moderate COVID-19 was not (aHR: 0.68, 95% CI: 0.38–1.23). CONCLUSION: In this case–control study, COVID-19 did not have a long-term impact on the disease course of IBD. However, severe COVID-19 was numerically associated with worse IBD outcomes, underscoring the continued importance of risk mitigation and prevention strategies for patients with IBD during the ongoing COVID-19 pandemic. |
format | Online Article Text |
id | pubmed-9637830 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-96378302022-11-07 COVID-19 is not associated with worse long-term inflammatory bowel disease outcomes: a multicenter case–control study Hong, Simon J. Bhattacharya, Sumona Aboubakr, Aiya Nadkarni, Devika Lech, Diana Ungaro, Ryan C. Agrawal, Manasi Hirten, Robert P. Greywoode, Ruby Mone, Anjali Chang, Shannon Hudesman, David P. Ullman, Thomas Sultan, Keith Lukin, Dana J. Colombel, Jean-Frederic Axelrad, Jordan E. Therap Adv Gastroenterol The Impact of COVID-19 in Gastrointestinal Diseases BACKGROUND: Inflammatory bowel disease (IBD) is not associated with worse coronavirus disease 2019 (COVID-19) outcomes. However, data are lacking regarding the long-term impact of severe acute respiratory syndrome coronavirus 2 infection on the disease course of IBD. OBJECTIVES: We aimed to investigate the effect of COVID-19 on long-term outcomes of IBD. DESIGN: We performed a multicenter case–control study of patients with IBD and COVID-19 between February 2020 and December 2020. METHODS: Cases and controls were individuals with IBD with presence or absence, respectively, of COVID-19-related symptoms and confirmatory testing. The primary composite outcome was IBD-related hospitalization or surgery. RESULTS: We identified 251 cases [ulcerative colitis (n = 111, 45%), Crohn’s disease (n = 139, 55%)] and 251 controls, with a median follow-up of 394 days. The primary composite outcome of IBD-related hospitalization or surgery occurred in 29 (12%) cases versus 38 (15%) controls (p = 0.24) and on multivariate Cox regression, COVID-19 was not associated with increased risk of adverse IBD outcomes [adjusted hazard ratio (aHR): 0.84, 95% confidence interval [CI]: 0.44–1.42]. When stratified by infection severity, severe COVID-19 was associated with a numerically increased risk of adverse IBD outcomes (aHR: 2.43, 95% CI: 1.00–5.86), whereas mild-to-moderate COVID-19 was not (aHR: 0.68, 95% CI: 0.38–1.23). CONCLUSION: In this case–control study, COVID-19 did not have a long-term impact on the disease course of IBD. However, severe COVID-19 was numerically associated with worse IBD outcomes, underscoring the continued importance of risk mitigation and prevention strategies for patients with IBD during the ongoing COVID-19 pandemic. SAGE Publications 2022-11-04 /pmc/articles/PMC9637830/ /pubmed/36348637 http://dx.doi.org/10.1177/17562848221132363 Text en © The Author(s), 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | The Impact of COVID-19 in Gastrointestinal Diseases Hong, Simon J. Bhattacharya, Sumona Aboubakr, Aiya Nadkarni, Devika Lech, Diana Ungaro, Ryan C. Agrawal, Manasi Hirten, Robert P. Greywoode, Ruby Mone, Anjali Chang, Shannon Hudesman, David P. Ullman, Thomas Sultan, Keith Lukin, Dana J. Colombel, Jean-Frederic Axelrad, Jordan E. COVID-19 is not associated with worse long-term inflammatory bowel disease outcomes: a multicenter case–control study |
title | COVID-19 is not associated with worse long-term inflammatory bowel
disease outcomes: a multicenter case–control study |
title_full | COVID-19 is not associated with worse long-term inflammatory bowel
disease outcomes: a multicenter case–control study |
title_fullStr | COVID-19 is not associated with worse long-term inflammatory bowel
disease outcomes: a multicenter case–control study |
title_full_unstemmed | COVID-19 is not associated with worse long-term inflammatory bowel
disease outcomes: a multicenter case–control study |
title_short | COVID-19 is not associated with worse long-term inflammatory bowel
disease outcomes: a multicenter case–control study |
title_sort | covid-19 is not associated with worse long-term inflammatory bowel
disease outcomes: a multicenter case–control study |
topic | The Impact of COVID-19 in Gastrointestinal Diseases |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9637830/ https://www.ncbi.nlm.nih.gov/pubmed/36348637 http://dx.doi.org/10.1177/17562848221132363 |
work_keys_str_mv | AT hongsimonj covid19isnotassociatedwithworselongterminflammatoryboweldiseaseoutcomesamulticentercasecontrolstudy AT bhattacharyasumona covid19isnotassociatedwithworselongterminflammatoryboweldiseaseoutcomesamulticentercasecontrolstudy AT aboubakraiya covid19isnotassociatedwithworselongterminflammatoryboweldiseaseoutcomesamulticentercasecontrolstudy AT nadkarnidevika covid19isnotassociatedwithworselongterminflammatoryboweldiseaseoutcomesamulticentercasecontrolstudy AT lechdiana covid19isnotassociatedwithworselongterminflammatoryboweldiseaseoutcomesamulticentercasecontrolstudy AT ungaroryanc covid19isnotassociatedwithworselongterminflammatoryboweldiseaseoutcomesamulticentercasecontrolstudy AT agrawalmanasi covid19isnotassociatedwithworselongterminflammatoryboweldiseaseoutcomesamulticentercasecontrolstudy AT hirtenrobertp covid19isnotassociatedwithworselongterminflammatoryboweldiseaseoutcomesamulticentercasecontrolstudy AT greywooderuby covid19isnotassociatedwithworselongterminflammatoryboweldiseaseoutcomesamulticentercasecontrolstudy AT moneanjali covid19isnotassociatedwithworselongterminflammatoryboweldiseaseoutcomesamulticentercasecontrolstudy AT changshannon covid19isnotassociatedwithworselongterminflammatoryboweldiseaseoutcomesamulticentercasecontrolstudy AT hudesmandavidp covid19isnotassociatedwithworselongterminflammatoryboweldiseaseoutcomesamulticentercasecontrolstudy AT ullmanthomas covid19isnotassociatedwithworselongterminflammatoryboweldiseaseoutcomesamulticentercasecontrolstudy AT sultankeith covid19isnotassociatedwithworselongterminflammatoryboweldiseaseoutcomesamulticentercasecontrolstudy AT lukindanaj covid19isnotassociatedwithworselongterminflammatoryboweldiseaseoutcomesamulticentercasecontrolstudy AT colombeljeanfrederic covid19isnotassociatedwithworselongterminflammatoryboweldiseaseoutcomesamulticentercasecontrolstudy AT axelradjordane covid19isnotassociatedwithworselongterminflammatoryboweldiseaseoutcomesamulticentercasecontrolstudy |